ISSN: 1875-6212 (Online)
ISSN: 1570-1611 (Print)

Volume 15, 6 Issues, 2017

Download PDF Flyer

Current Vascular Pharmacology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 36th of 63 in Peripheral Vascular Disease
  • 125th of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Dimitri P. Mikhailidis
Academic Head, Department of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street
London, NW3 2QG

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.391
5 - Year: 2.262

Upcoming Articles (E-Pub Abstracts ahead of Print)

NAFLD-NASH: an under-recognized epidemic

Joseph Jennings, Charles Faselis and Michael D Yao.

View Abstract

Patients with acute coronary syndrome are at high risk prior to the event and lipid management is underachieved pre- and post-hospitalization

C. Vlachopoulos, G. Andrikopoulos, D. Terentes-Printzios, S. Tzeis, E. K. Iliodromitis, D. Richter, I. Mantas, A. Kartalis, V. Vasilikos, D. Stakos, S. Patsilinakos, S. Lampropoulos, D. Symeonidis, C. Kyrpizidis, N. Marinakis, N. Nikas, J. Lekakis, D. Tousoulis and P Vardas.

View Abstract

Nonalcoholic fatty liver disease vs. nonalcoholic steatohepatitis: pathological and clinical implications

Chrysoula Boutari, Petros Lefkos, Vasilios G. Athyros, Asterios Karagiannis and Konstantinos Tziomalos.

View Abstract

Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk

Vasilios G. Athyros, Chrysa Boutari, Konstantinos Stavropoulos, Panagiotis Anagnostis, Konstantinos P. Imprialos, Michael Doumas and Asterios Karagiannis.

View Abstract

Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving

Thomas F Whayne.

View Abstract

Current and potential future pharmacological approaches for non-alcoholic fatty liver disease

Konstantinos Imprialos, Konstantinos Stavropoulos, Sofia Bouloukou, Georgios Kerpiniotis, Asterios Karagiannis and Michael Doumas.

View Abstract

Can serum uric acid lowering therapy contribute to the prevention or treatment of nonalcoholic fatty liver disease?

Paschalis Paschos, Vasilios G. Athyros, Achilleas Tsimperidis, Anastasia Katsoula, Nikolaos Grammatikos and Olga Giouleme.

View Abstract

The co-existence of NASH and chronic kidney disease boosts cardiovascular risk: are there any common therapeutic options?

Marianna Papademetriou, Vasilios G. Athyros, Eleni Geladari, Michael Doumas, Costas Tsioufis and Vasilios Papademetriou.

View Abstract

Lifestyle modifications in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Konstantinos Stavropoulos, Konstantinos Imprialos, Andreas Pittaras, Charles Faselis, Puneet Narayan and Peter Kokkinos.

View Abstract

A Critical Approach of Guideline Therapeutic Recommendations for NAFLD

Dragan B. Djordjevic, Marija Zdravkovic, Aleksandar Nagorni, Athanasios Manolis, Costas Tsioufis and Dragan Lovic.

View Abstract

Is non-alcoholic fatty liver disease part of the metabolic syndrome?

Niki Katsiki, Dimitri P. Mikhailidis, Pablo Perez-Martinez, Panagiotis Anagnostis and Asterios Karagiannis.

View Abstract

Vascular Endothelial Growth Factor Inhibitor Therapy And Cardiovascular And Renal Damage In Renal Cell Carcinoma

Silvia Lai, Alessio Molfino, Patrizia Seminara, Flavia Longo, Georgie Innico, Bettina Coppola, Daniela Mastroluca, Alessandro Galani , Mira Dimko, Paola Aceto and Carlo Lai.

View Abstract

Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science